Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age

An inactivated poliovirus vaccine candidate using Sabin strains (sIPV) grown on the PER.C6® cell line was assessed in infants after demonstrated immunogenicity and safety in adults. The study recruited 300 infants who were randomized (1:1:1:1) to receive one of 3 dose levels of sIPV or a conventiona...

Descripción completa

Detalles Bibliográficos
Autores principales: Ong-Lim, Anna Lisa, Shukarev, Georgi, Trinidad-Aseron, Mitzi, Caparas-Yu, Delia, Greijer, Astrid, Duchene, Michel, Scheper, Gert, van Paassen, Vitalija, Le Gars, Mathieu, Cahill, Conor P., Schuitemaker, Hanneke, Douoguih, Macaya, Jacquet, Jeanne-Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Coronavirus – Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196784/
https://www.ncbi.nlm.nih.gov/pubmed/35344464
http://dx.doi.org/10.1080/21645515.2022.2044255

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196784/
https://www.ncbi.nlm.nih.gov/pubmed/35344464
http://dx.doi.org/10.1080/21645515.2022.2044255

Ejemplares similares